Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789431 | 0.88 | DPP4 (0.72) | DPP4TAAR1HRH3CD274LOXL2 | |
| SCHEMBL6448256 | 0.85 | TSHR (0.50) | DPP4PDCD1CD274LTB4R2PDK2 | |
| SCHEMBL7791854 | 0.84 | DPP4 (0.67) | DPP4TAAR1HRH3PDCD1CD274 | |
| SCHEMBL28089504 | 0.83 | TAAR1 (0.68) | DPP4TAAR1HRH3CD274LOXL2 | |
| SCHEMBL22400162 | 0.82 | CSNK2A1 (0.58) | DPP4TAAR1HRH3CD274LOXL2 | |
| SCHEMBL27724876 | 0.82 | DPP4 (0.53) | DPP4TAAR1HRH3CD274LOXL2 | |
| SCHEMBL809767 | 0.80 | TRPA1 (0.44) | DPP4PDCD1CD274LTB4R2PDK2 | |
| SCHEMBL8219997 | 0.79 | DPP4 (0.50) | DPP4TAAR1HRH3CD274LOXL2 | |
| SCHEMBL3786432 | 0.79 | DPP4 (0.48) | DPP4TAAR1PDCD1CD274LTB4R2 | |
| SCHEMBL7951583 | 0.79 | PDCD1 (0.61) | DPP4PDCD1CD274LTB4R2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | DPP4 1734/4885TAAR1 2654/4885HRH3 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.